Idenix Sues to Delay Market Entry of Gilead’s Competing Hep C Candidate

Drug Industry Daily
A A
Following setbacks to its hepatitis C drug program, Idenix Pharmaceuticals has turned to the courts to try to delay Gilead’s competitor hepatitis C treatment, claiming the drug infringes several Idenix-owned patents.

To View This Article:

Login

Subscribe To Drug Industry Daily